HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)
Status:
Recruiting
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, controlled, open-label study evaluating efficacy and
safety of perioperative FLOT chemotherapy plus intraoperative HIPEC versus FLOT chemotherapy
alone in patients with resectable localized and locally advanced diffuse and mixed type
adenocarcinoma of the stomach and Type II/III GEJ.